Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
The current ruling will assure the safety of the use of Ranitidine for Indian patients
EC grants conditional marketing authorization based on the EFFISAYIL trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
The hospital is being developed at a cost of more than Rs. 1,575 crore
Silodosin capsules treat signs and symptoms of an enlarged prostate gland
Expressed happiness that more than 30 countries of the world have given recognition to Ayurveda as a traditional system of medicine
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
Subscribe To Our Newsletter & Stay Updated
